Polaryx Therapeutics reported total assets of $11.81M and total liabilities of $0.87M for the quarter ended Jun 2026. This balance sheet covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Current Assets | ||||||
| Cash & EquivalentsCash & Equiv. | 4.62M | 5.14M | 3.08M | 11.54M | ||
| Cash & Current Investments | 4.62M | 5.14M | 3.08M | 11.54M | ||
| Receivables - OtherOther Receivables | 0.13M | 0.09M | ||||
| Prepaid Assets | 0.38M | 0.03M | 0.39M | 0.27M | ||
| Current Assets | 5.00M | 5.17M | 3.50M | 11.81M | ||
| Non-Current Assets | ||||||
| Assets | 5.00M | 5.17M | 3.50M | 11.81M | ||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payables | 0.07M | 0.47M | 0.85M | 0.68M | ||
| Payables | 0.07M | 0.47M | 0.85M | 0.68M | ||
| Accumulated Expenses | 0.09M | 0.02M | 0.04M | 0.07M | ||
| Other Accumulated Expenses | 0.13M | 0.09M | 0.10M | 0.10M | ||
| Total Current Liabilities | 0.29M | 0.60M | 1.01M | 0.87M | ||
| Non-Current Liabilities | ||||||
| Total Liabilities | 0.29M | -4.25M | -3.25M | 0.60M | 1.01M | 0.87M |
| Shareholder's Equity | ||||||
| Common Equity | 4.71M | 4.25M | 3.25M | 4.57M | 2.49M | 10.94M |
| Liabilities and Shareholders Equity | 5.00M | 5.17M | 3.50M | 11.81M | ||
| Retained Earnings | 95.36M | 104.19M | 104.66M | 114.49M |